- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hidradenitis suppurativa (HS)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Bimekizumab – May 2025
Bimekizumab: Injection 160 mg in 1 mL single use pre-filled pen, Injection 160 mg in 1 mL single use pre-filled syringe, Injection 320 mg in 2 mL single use pre-filled pen, Injection 320 mg in 2 mL single use pre-filled syringe; Bimzelx®
Last updated
9 May 2025
